Dr. Reddy's Laboratories Beheer
Beheer criteriumcontroles 2/4
De CEO Dr. Reddy's Laboratories is Erez Israeli, benoemd in Apr2018, heeft een ambtstermijn van 6.58 jaar. bezit rechtstreeks 0.007% van de aandelen van het bedrijf, ter waarde ₹ 65.07M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 6.6 jaar en 2.8 jaar.
Belangrijke informatie
Erez Israeli
Algemeen directeur
₹197.1m
Totale compensatie
| Percentage CEO-salaris | n/a |
| Dienstverband CEO | 6.6yrs |
| Eigendom CEO | 0.007% |
| Management gemiddelde ambtstermijn | 6.6yrs |
| Gemiddelde ambtstermijn bestuur | 2.8yrs |
Recente managementupdates
Recent updates
Are Dr. Reddy's Laboratories Limited (NSE:DRREDDY) Investors Paying Above The Intrinsic Value?
Nov 23
Dr. Reddy's Laboratories Limited Just Missed EPS By 12%: Here's What Analysts Think Will Happen Next
Nov 08Insufficient Growth At Dr. Reddy's Laboratories Limited (NSE:DRREDDY) Hampers Share Price
Nov 01Is Dr. Reddy's Laboratories (NSE:DRREDDY) Using Too Much Debt?
Oct 14If EPS Growth Is Important To You, Dr. Reddy's Laboratories (NSE:DRREDDY) Presents An Opportunity
Aug 19Dr. Reddy's Laboratories Limited (NSE:DRREDDY) Exceeded Expectations And The Analyst Consensus Has Been Reviewing Its Models
Aug 01The Market Doesn't Like What It Sees From Dr. Reddy's Laboratories Limited's (NSE:DRREDDY) Earnings Yet
Jul 30Dr. Reddy's Laboratories (NSE:DRREDDY) Seems To Use Debt Rather Sparingly
Jul 12Dr. Reddy's Laboratories (NSE:DRREDDY) Will Pay A Dividend Of ₹40.00
Jun 23Additional Considerations Required While Assessing Dr. Reddy's Laboratories' (NSE:DRREDDY) Strong Earnings
Jun 20Dr. Reddy's Laboratories (NSE:DRREDDY) Is Paying Out A Dividend Of ₹40.00
May 26Dr. Reddy's Laboratories (NSE:DRREDDY) Will Pay A Dividend Of ₹40.00
May 10With EPS Growth And More, Dr. Reddy's Laboratories (NSE:DRREDDY) Makes An Interesting Case
May 06There Is A Reason Dr. Reddy's Laboratories Limited's (NSE:DRREDDY) Price Is Undemanding
Apr 18Earnings Beat: Dr. Reddy's Laboratories Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
Feb 02Should You Be Adding Dr. Reddy's Laboratories (NSE:DRREDDY) To Your Watchlist Today?
Jan 19Why Investors Shouldn't Be Surprised By Dr. Reddy's Laboratories Limited's (NSE:DRREDDY) Low P/E
Jan 01Dr. Reddy's Laboratories (NSE:DRREDDY) Has A Rock Solid Balance Sheet
Oct 21If EPS Growth Is Important To You, Dr. Reddy's Laboratories (NSE:DRREDDY) Presents An Opportunity
Oct 03Dr. Reddy's Laboratories (NSE:DRREDDY) Could Easily Take On More Debt
Jul 14Dr. Reddy's Laboratories (NSE:DRREDDY) Is Increasing Its Dividend To ₹40.00
Jun 24Dr. Reddy's Laboratories (NSE:DRREDDY) Is Paying Out A Larger Dividend Than Last Year
Jun 10Dr. Reddy's Laboratories (NSE:DRREDDY) Is Increasing Its Dividend To ₹40.00
May 27Dr. Reddy's Laboratories' (NSE:DRREDDY) Dividend Will Be Increased To ₹40.00
May 13Is Dr. Reddy's Laboratories (NSE:DRREDDY) Using Too Much Debt?
Apr 11If EPS Growth Is Important To You, Dr. Reddy's Laboratories (NSE:DRREDDY) Presents An Opportunity
Mar 06These 4 Measures Indicate That Dr. Reddy's Laboratories (NSE:DRREDDY) Is Using Debt Reasonably Well
Jan 10If EPS Growth Is Important To You, Dr. Reddy's Laboratories (NSE:DRREDDY) Presents An Opportunity
Dec 05Analyse CEO-vergoeding
| Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | ₹53b |
| Jun 30 2024 | n/a | n/a | ₹56b |
| Mar 31 2024 | ₹197m | n/a | ₹56b |
| Dec 31 2023 | n/a | n/a | ₹52b |
| Sep 30 2023 | n/a | n/a | ₹51b |
| Jun 30 2023 | n/a | n/a | ₹47b |
| Mar 31 2023 | ₹195m | n/a | ₹45b |
| Dec 31 2022 | n/a | n/a | ₹36b |
| Sep 30 2022 | n/a | n/a | ₹31b |
| Jun 30 2022 | n/a | n/a | ₹30b |
| Mar 31 2022 | ₹127m | n/a | ₹24b |
| Dec 31 2021 | n/a | n/a | ₹26b |
| Sep 30 2021 | n/a | n/a | ₹19b |
| Jun 30 2021 | n/a | n/a | ₹17b |
| Mar 31 2021 | ₹120m | n/a | ₹17b |
| Dec 31 2020 | n/a | n/a | ₹21b |
| Sep 30 2020 | n/a | n/a | ₹15b |
| Jun 30 2020 | n/a | n/a | ₹19b |
| Mar 31 2020 | ₹195m | ₹107m | ₹19b |
| Dec 31 2019 | n/a | n/a | ₹16b |
| Sep 30 2019 | n/a | n/a | ₹27b |
| Jun 30 2019 | n/a | n/a | ₹21b |
| Mar 31 2019 | ₹123m | n/a | ₹19b |
Compensatie versus markt: De totale vergoeding ($USD 2.33M ) Erez } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de Indian markt ($USD 1.08M ).
Compensatie versus inkomsten: De vergoeding van Erez is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.
CEO
Erez Israeli (56 yo)
6.6yrs
Tenure
₹197,090,000
Compensatie
Mr. Erez Israeli, MBA has been Chief Executive Officer of Dr. Reddy's Laboratories Limited since August 1, 2019 and has been its Member of the Management Council since April 02, 2018. Mr. Israeli served as...
Leiderschapsteam
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| Co-Chairman | 38.6yrs | ₹186.28m | 13.07% ₹ 129.9b | |
| Chairman of the Board & Member of the Management Council | 31.8yrs | ₹116.17m | 13.61% ₹ 135.2b | |
| CEO & Member of the Management Council | 6.6yrs | ₹197.09m | 0.0066% ₹ 65.1m | |
| CFO & Member of the Management Council | less than a year | ₹48.82m | 0.0057% ₹ 56.3m | |
| Global Head of Quality and Pharmacovigilance & Member of the Management Council | less than a year | ₹6.15m | geen gegevens | |
| CEO of API & Services & Member of Management Council | no data | ₹41.90m | 0.0027% ₹ 26.6m | |
| CEO of Branded Markets - India & Emerging Countries and Member of Management Council | no data | ₹82.74m | 0.016% ₹ 156.3m | |
| EVP, Head of Corporate Communications | 7.4yrs | ₹65.21m | 0.0063% ₹ 63.1m | |
| Executive VP | 7.3yrs | ₹66.05m | geen gegevens | |
| CEO of European Generics & Member of Management Council | no data | ₹63.09m | geen gegevens | |
| Global Head of Integrated Product Development Organisation & Member of the Management Council | no data | ₹55.63m | 0.000020% ₹ 198.7k | |
| Global Head – Biologics & Member of the Management Council | no data | ₹34.59m | geen gegevens |
6.6yrs
Gemiddelde duur
56yo
Gemiddelde leeftijd
Ervaren management: Het managementteam van DRREDDY is doorgewinterd en ervaren (gemiddelde ambtstermijn van 6.6 jaar).
Bestuursleden
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| Co-Chairman | 38.6yrs | ₹186.28m | 13.07% ₹ 129.9b | |
| Chairman of the Board & Member of the Management Council | 31.8yrs | ₹116.17m | 13.61% ₹ 135.2b | |
| Member of the Scientific Advisory Board | no data | ₹8.36m | geen gegevens | |
| Independent Director | 2.3yrs | ₹18.77m | geen gegevens | |
| Independent Director | 5.8yrs | ₹13.34m | geen gegevens | |
| Member of the Scientific Advisory Board | no data | geen gegevens | geen gegevens | |
| Lead Independent Director | 6.1yrs | ₹17.10m | geen gegevens | |
| Independent Director | 2.8yrs | ₹14.18m | geen gegevens | |
| Independent Director | less than a year | ₹3.32m | geen gegevens | |
| Independent Director | 1.8yrs | ₹8.25m | geen gegevens | |
| Independent Director | 2.8yrs | ₹17.10m | geen gegevens | |
| Independent Director | 1.5yrs | ₹16.09m | geen gegevens |
2.8yrs
Gemiddelde duur
64yo
Gemiddelde leeftijd
Ervaren bestuur: De raad van bestuur van DRREDDY wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 2.8 jaar), wat duidt op een nieuw bestuur.